Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for rare disease: can NS-229 help patients reduce steroids?

NCT ID NCT06046222

Ongoing Disease control Sponsor: NS Pharma, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new medicine, NS-229, in 45 adults with a rare disease called eosinophilic granulomatosis with polyangiitis (EGPA), which causes inflammation in blood vessels. The goal is to see if NS-229 can help patients achieve remission while lowering their daily steroid dose. Participants will receive either NS-229 or a placebo, and doctors will check disease activity and steroid use after 28 weeks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHURG-STRAUSS SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

eosinophilic granulomatosis with polyangiitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHURG-STRAUSS SYNDROME EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS

Contacts and locations

Locations

  • Addenbrookes Hospital

    Cambridge, CB2 2QQ, United Kingdom

  • Azienda Ospedaliera Universitaria Integrata Verona

    Verona, 37126, Italy

  • Azienda Provinciale per i Servizi Sanitari Provincia Autonoma Trento

    Trento, 38122, Italy

  • CHU Nice

    Nice, 06202, France

  • Chiba University Hospital

    Chuo-ku, Chiba-shi, Chiba, 260-8677, Japan

  • Chu Rangueil

    Toulouse, 31059, France

  • Cleveland Clinic

    Cleveland, Ohio, 44195, United States

  • Complejo Hospitalario Universitario de Santiago de Compostela

    Santiago de Compostela, A Coruna, 15706, Spain

  • Complejo Hospitalario de Navarra

    Pamplona, 31008, Spain

  • Fondazione Policlinico Universitario Campus Bio-Medico

    Roma, 00128, Italy

  • Hokkaido University Hospital

    Sapporo, Hokkaido, 060-8648, Japan

  • Hopital Cochin

    Paris, 75014, France

  • Hospital of the University of Occupational and Environmental Health, Japan

    Kitakyushu, Fukuoka, 807-8555, Japan

  • Istituto Auxologico Italiano IRCCS

    Milan, 20145, Italy

  • Juntendo University Hospital

    Bunkyo-ku, Tokyo, 113-8431, Japan

  • Kyorin University Hospital

    Mitaka, Tokyo, 181-8611, Japan

  • Mayo Clinic

    Rochester, Minnesota, 55905, United States

  • Medical University of South Carolina

    Charleston, South Carolina, 29425, United States

  • Medius Kliniken gGmbh

    Kirchheim unter Teck, Studienzentrale, 73230, Germany

  • NHO Sagamihara National Hospital

    Sagamihara, Kanagawa, 252-0392, Japan

  • National Hospital Organization Yokohama Medical Center

    Yokohama, Kanagawa, 245-8575, Japan

  • National Jewish Health

    Denver, Colorado, 80206, United States

  • Osaka Habikino Medical Center

    Habikino, Osaka, 583-8588, Japan

  • Queen Elizabeth Hospital Birmingham

    Edgbaston, Birmingham, B15 2GW, United Kingdom

  • Royal Berkshire NHS Foundation Trust

    Reading, RG1 5AN, United Kingdom

  • Saitama Medical Center

    Kawagoe, Saitama, 350-8550, Japan

  • St Joseph's Healthcare Hamilton

    Hamilton, Ontario, L8N4A6, Canada

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio, 43210, United States

  • Toho University Omori Medical Center

    Ōta-ku, Tokyo, 143-8541, Japan

  • Tohoku University Hospital

    Sendai, Miyagi, 980-8574, Japan

  • University of Alberta

    Edmonton, Alberta, T6G 2B7, Canada

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

  • University of Toronto

    Toronto, Ontario, M5G 1X5, Canada

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.